COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis
Yu Zheng(Howard Hughes Medical Institute), Daniel A. Haber(Howard Hughes Medical Institute), Shruthi Rengarajan(Harvard University), David T. Miyamoto(Broad Institute), David T. Ting(Massachusetts General Hospital), Miguel N. Rivera(University of North Texas), Anupriya S. Kulkarni(Massachusetts General Hospital), Katherine Broderick(Harvard University), Gaylor Boulay(Harvard University), Chin‐Lee Wu(Massachusetts General Hospital), Ben S. Wittner(Broad Institute), Eric C. Tai(Massachusetts General Hospital), Shyamala Maheswaran(Massachusetts General Hospital), Mehmet Toner(Center for Cancer Research), Srinjoy Sil(Massachusetts General Hospital), Michael W. Koulopoulos(Harvard University), Risa Burr(Harvard University), Valentine Comaills(Harvard University), Toshi Shioda(Center for Cancer Research), Sridhar Ramaswamy(Harvard University), Erin Emmons(Harvard University)
Cited by 48
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
|Cell|2004|3.8k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
|Endocrine Reviews|2012|3.1k